Matti Lehtinen

Community-randomized trial database and HPV vaccination

Dr Matti Lehtinen, of the University of Tampere, Finland, notes how IARC models were used and validated in Finland to determine the most feasible approach to reducing the burden of human papillomavirus (HPV) infection. This is important to high-income as well as low- and middle-income countries in designing their vaccination programmes.

  • Country: Finland
  • Cancer type or topic: Cervical